Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMEX: Gefitinib vs Methotrexate in Head and Neck Cancer
NCT00206219Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2003
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of gefitinib in squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by AstraZeneca. Primary endpoint: Overall Survival. Started Nov 2003; status: completed.
02
Drugs
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT00206219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00206219.